Kamal Joshi | Principal Scientist
Bristol Myers Squibb

Kamal Joshi, Principal Scientist, Bristol Myers Squibb

Kamal Joshi is a Principal Scientist and Group Leader in Discovery Biotherapeutics at Bristol Myers Squibb (BMS), where he leads the development of next-generation multispecific antibodies and T-cell engager therapies for cancer. His work focuses on protein engineering, antibody discovery, and AI-enabled biologics innovation to advance novel immunotherapies. Prior to BMS, he conducted antibody engineering research at Genentech and earned his Ph.D. in Biochemistry and Molecular Biology from the University of Massachusetts Amherst.

 

Appearances:



Festival of Biologics Day 2 @ 15:00

Engineering Next-Generation T-Cell Engagers for Solid Tumors

·  Developed a multispecific TCE platform integrating tumor targeting, T-cell engagement, and costimulation.

·  Optimized TCEs enhanced T-cell activation, persistence, and tumor cell killing in preclinical studies.

·  Integrated costimulation may improve the potency and durability of TCEs for solid tumors

last published: 18/Nov/26 17:29 GMT

back to speakers

Get involved at Festival of Biologics USA 2027

 

 

TO SPONSOR


Nicholas Matthews

Nicholas.Matthews@terrapinn.com

 

 

TO SPEAK


Jack Beard
Jack.Beard@terrapinn.com

 

MARKETING & PRESS


Ollie McDaid

Ollie.Mcdaid@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.